Eric Delay, MD
Internal Medicine · Morristown, TNNPI 1366460412
Payments from drug & device makers
Across 231 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$394
- AbbVie$358
- GSK$265
- Boehringer Ingelheim$188
- Pfizer$150
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,611100%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 77 | $1,038 |
| AstraZeneca | 21 | $394 |
| AbbVie(2 entities) | 24 | $358 |
| GSK | 16 | $265 |
| Boehringer Ingelheim | 12 | $188 |
| Pfizer | 10 | $150 |
| Idorsia Pharmaceuticals US Inc | 6 | $103 |
| Sanofi-aventis U.S. LLC | 7 | $94 |
| Corium, LLC | 4 | $77 |
| Merck | 5 | $75 |
| Lilly USA, LLC | 5 | $73 |
| Amarin Pharma, Inc. | 4 | $72 |
| Johnson & Johnson | 5 | $71 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Medtronic(2 entities) | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Ardelyx, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 1 | $36 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Amgen | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Grifols USA, LLC | 1 | $20 |
| Abiomed | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $19 |
| Novartis | 1 | $18 |
| Cranial Technologies, Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Optos, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$3,624 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 274 | $330,280 |
| JardianceEmpagliflozin | 249 | $256,479 |
| MounjaroTirzepatide | 105 | $143,246 |
| EliquisApixaban | 142 | $124,371 |
| FarxigaDapagliflozin Propanediol | 128 | $119,583 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $110,510 |
| TrulicityDulaglutide | 79 | $96,048 |
| XifaxanRifaximin | 22 | $74,220 |
| XareltoRivaroxaban | 61 | $60,760 |
| LinzessLinaclotide | 95 | $59,965 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $52,336 |
| RybelsusSemaglutide | 17 | $34,521 |
| JanuviaSitagliptin Phosphate | 34 | $31,633 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $29,701 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $29,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,038 | $364,800291 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $188 | $273,674286 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $239,294184 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix, Anoro Ellipta | $265 | $190,742346 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium, Symbicort | $394 | $157,042196 claims |
| PfizerEliquis | $150 | $124,371142 claims |
| AbbVieLinzess, Ubrelvy, Creon | $358 | $102,023127 claims |
| MerckJanuvia, Janumet | $75 | $61,33451 claims |
| Johnson & JohnsonXarelto | $71 | $60,76061 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $94 | $52,33643 claims |
| NovartisEntresto | $18 | $17,88319 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $7,5151,074 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Morristown
- Paul CardaliMorristown$144K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.